Peter McLaughlin
Overview
Explore the profile of Peter McLaughlin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2980
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grote M, Te Heesen A, McLaughlin P, Rheinberger H
Ber Wiss
. 2021 Sep;
44(3):267-280.
PMID: 34467540
No abstract available.
2.
Samaniego F, McLaughlin P, Neelapu S, Feng L, Fanale M, Nastoupil L, et al.
Leuk Lymphoma
. 2020 Sep;
62(1):58-67.
PMID: 32924687
R-FND (rituximab, fludarabine, mitoxantrone, and dexamethasone) can induce molecular remissions in indolent lymphoma. The addition of yttrium ibritumomab tiuxetan (YIT) radioimmunotherapy following first-line induction treatment in patients with advanced follicular...
3.
Ejeahalaka K, McLaughlin P, On S
Food Chem
. 2020 Aug;
339:127844.
PMID: 32829243
Fat-filled milk powders (FMP) are inexpensive milk alternatives predominantly exported to developing countries to satisfy growing demands for dairy proteins. Harsh climatic and sanitary conditions, poor border controls and relatively...
4.
Khashab T, Hagemeister F, Romaguera J, Fanale M, Pro B, McLaughlin P, et al.
Br J Haematol
. 2019 Mar;
185(4):670-678.
PMID: 30820940
In a prospective phase II trial, pentostatin combined with cyclophosphamide and rituximab (PCR) induced strong responses and was well-tolerated in previously untreated patients with advanced-stage, indolent non-Hodgkin lymphoma (iNHL). After...
5.
Romaguera J, Wang M, Feng L, Fayad L, Hagemeister F, McLaughlin P, et al.
Cancer
. 2018 May;
124(12):2561-2569.
PMID: 29723393
Background: Although the outcomes of patients with mantle cell lymphoma (MCL) have improved, there is still no cure. Bortezomib has a 33% response rate in relapsed/refractory MCL and has shown...
6.
Fanale M, Cheah C, Rich A, Medeiros L, Lai C, Oki Y, et al.
Blood
. 2017 May;
130(4):472-477.
PMID: 28522441
Nodular lymphocyte Hodgkin lymphoma (NLPHL) is a rare disease for which the optimal therapy is unknown. We hypothesized that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) could decrease rates...
7.
Hwang J, Suarez-Almazor M, Cantor S, Barbo A, Lin H, Ahmed S, et al.
Cancer
. 2017 May;
123(17):3367-3376.
PMID: 28518219
Background: Data on the incidence of adverse liver outcomes are limited for cancer patients with chronic (hepatitis B surface antigen [HBsAg]-positive/hepatitis B core antibody [anti-HBc]-positive) or past (HBsAg-negative/anti-HBc-positive) hepatitis B...
8.
Nastoupil L, McLaughlin P, Feng L, Neelapu S, Samaniego F, Hagemeister F, et al.
Br J Haematol
. 2017 Mar;
177(2):263-270.
PMID: 28340281
We report a single-centre, randomized study evaluating the efficacy and safety of concurrent fludarabine, mitoxantrone, dexamethasone (FND) and rituximab versus sequential FND followed by rituximab in 158 patients with advanced...
9.
Sarris A, Jiang Y, Tsimberidou A, Thomaides A, Rassidakis G, Ford R, et al.
Semin Oncol
. 2017 Feb;
29(1S2):48-55.
PMID: 28140092
Fludarabine and rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals, San Diego, CA) are active against indolent lymphomas. We have previously shown the safety and efficacy of...
10.
Chen Y, Neelapu S, Feng L, Bi W, Yang T, Wang M, et al.
Br J Haematol
. 2016 Jul;
175(2):290-299.
PMID: 27448187
There are limited reports that baseline peripheral absolute neutrophil count (ANC), absolute monocyte count (AMC), absolute lymphocyte count (ALC) and serum β2-microglobulin level independently predict survival in patients with diffuse...